LOS ANGELES — California s Covid numbers are on the rise thanks, in part, to new subvariants, suggesting an earlier-than-normal start to the summer season.
Moderna, Inc. (NASDAQ: MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus responsible for the 2020 pandemic.
By Sabela Ojea The Food and Drug Administration has recommended that manufacturers of Covid-19 vaccines should focus on the JN.1 variant beginning in the fall of 2024. The FDA s Vaccines. -June 07, 2024 at 05:45 pm EDT
- MarketScreener